Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7.
Fosså SD, Wiklund F, Klepp O, Angelsen A, Solberg A, Damber JE, Hoyer M, Widmark A; The Scandinavian Prostate Cancer Group-7 Investigators. Fosså SD, et al. Among authors: angelsen a. Eur Urol. 2016 Oct;70(4):684-691. doi: 10.1016/j.eururo.2016.03.021. Epub 2016 Mar 26. Eur Urol. 2016. PMID: 27025586 Clinical Trial.
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fosså SD; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3. Widmark A, et al. Among authors: angelsen a. Lancet. 2009 Jan 24;373(9660):301-8. doi: 10.1016/S0140-6736(08)61815-2. Epub 2008 Dec 16. Lancet. 2009. PMID: 19091394 Free article. Clinical Trial.
Side-effects of post-treatment biopsies in prostate cancer patients treated with endocrine therapy alone or combined with radical radiotherapy in the Scandinavian Prostate Cancer Group-7 randomized trial.
Solberg A, Widmark A, Tasdemir I, Ahlgren G, Angelsen A. Solberg A, et al. Among authors: angelsen a. Scand J Urol Nephrol. 2011 Sep;45(4):233-8. doi: 10.3109/00365599.2011.560577. Epub 2011 Mar 31. Scand J Urol Nephrol. 2011. PMID: 21452932 Clinical Trial.
Does a surgeon's annual radical prostatectomy volume predict the risk of positive surgical margins and urinary incontinence at one-year follow-up? Findings from a prospective national study.
Steinsvik EA, Axcrona K, Angelsen A, Beisland C, Dahl A, Eri LM, Haug ES, Svindland A, Fosså S. Steinsvik EA, et al. Among authors: angelsen a. Scand J Urol. 2013 Apr;47(2):92-100. doi: 10.3109/00365599.2012.707684. Epub 2012 Aug 6. Scand J Urol. 2013. PMID: 22860630
Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
Ahlgren GM, Flodgren P, Tammela TLJ, Kellokumpu-Lehtinen P, Borre M, Angelsen A, Iversen JR, Sverrisdottir A, Jonsson E, Sengelov L; Investigators of the Scandinavian Prostate Cancer Study Number 12. Ahlgren GM, et al. Among authors: angelsen a. Eur Urol. 2018 Jun;73(6):870-876. doi: 10.1016/j.eururo.2018.01.012. Epub 2018 Feb 1. Eur Urol. 2018. PMID: 29395502 Clinical Trial.
[Incorrect about hormone treatment in prostatic cancer].
Fosså SD, Egey A, Haukaas SA, Angelsen A, Klepp O, Berge V, Axcrona K, Lilleby W. Fosså SD, et al. Among authors: angelsen a. Tidsskr Nor Laegeforen. 2009 Feb 26;129(5):429. doi: 10.4045/tidsskr.08.0649. Tidsskr Nor Laegeforen. 2009. PMID: 19247406 Free article. Norwegian. No abstract available.
72 results